- Home
- OXM vs OCS Comparison
OXM vs OCS Comparison
Compare OXM & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- OCS
- Stock Information
- Founded
- OXM 1942
- OCS 2003
- Country
- OXM United States
- OCS Switzerland
- Employees
- OXM N/A
- OCS N/A
- Industry
- OXM Apparel
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- OXM Consumer Discretionary
- OCS Health Care
- Exchange
- OXM Nasdaq
- OCS Nasdaq
- Market Cap
- OXM 958.1M
- OCS 904.3M
- IPO Year
- OXM N/A
- OCS N/A
- Fundamental
- Price
- OXM $58.97
- OCS $19.18
- Analyst Decision
- OXM Hold
- OCS Strong Buy
- Analyst Count
- OXM 5
- OCS 4
- Target Price
- OXM $66.50
- OCS $29.50
- AVG Volume (30 Days)
- OXM 549.9K
- OCS 42.7K
- Earning Date
- OXM 03-27-2025
- OCS 03-11-2025
- Dividend Yield
- OXM 4.64%
- OCS N/A
- EPS Growth
- OXM 53.66
- OCS N/A
- EPS
- OXM 5.87
- OCS N/A
- Revenue
- OXM $1,516,601,000.00
- OCS $757,024.00
- Revenue This Year
- OXM $3.65
- OCS $927.26
- Revenue Next Year
- OXM $2.74
- OCS $292.79
- P/E Ratio
- OXM $10.14
- OCS N/A
- Revenue Growth
- OXM N/A
- OCS N/A
- 52 Week Low
- OXM $53.23
- OCS $10.55
- 52 Week High
- OXM $111.46
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- OXM 37.90
- OCS 44.64
- Support Level
- OXM $60.34
- OCS $18.30
- Resistance Level
- OXM $64.39
- OCS $20.00
- Average True Range (ATR)
- OXM 3.01
- OCS 0.64
- MACD
- OXM 0.77
- OCS 0.13
- Stochastic Oscillator
- OXM 51.39
- OCS 67.33
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates a majority of its revenue from the Tommy Bahama division.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.